Search | Clinical Trials Finder

Conditions: Hepatitis C, Liver Disease
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Years and older
Enrollment: 870 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Prevention, Sexually Transmitted Infections (STI), Preexposure Prophylaxis (PrEP), Incarceration, Hepatitis C Virus (HCV), Substance Use Disorder (SUD)
Interventions: Mobile Enhanced Prevention Support (MEPS), Control; Behavioral · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 59 Years · Male only
Enrollment: 318 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Oakland, California • Riverside, California

Conditions: Hepatitis C, Chronic
Interventions: Telaprevir, pegylated interferon (Peg-IFN) alfa-2a, ribavirin (RBV); Drug
Lead sponsor: Janssen Infectious Diseases BVBA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 14
States / cities: Coronado, California • Los Angeles, California • San Francisco, California + 11 more

Conditions: Hepatitis C, Chronic
Interventions: Epclusa (SOF/VEL), Standard of care, Fibroscan® 430 Mini Plus; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 64 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Hepatitis C, Obesity
Interventions: Not listed
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hepatitis C
Interventions: Pegylated Interferon Lambda (pegIFNλ), BMS-790052 (NS5A Inhibitor), Ribavirin (RBV), BMS-650032 (NS3 Protease Inhibitor), Pegylated Interferon Alfa-2a (pegIFNα-2a), Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor), Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor), Placebo for Ribavirin (RBV); Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Phoenix, Arizona • Palm Springs, California • Aurora, Colorado + 10 more

Conditions: Healthy
Interventions: MBL-HCV1; Biological
Lead sponsor: MassBiologics; Other
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Hepatitis C
Interventions: Pegylated Interferon alfa-2b, Simeprevir, Ribavirin, Sofosbuvir; Drug
Lead sponsor: Center For Hepatitis C, Atlanta, GA; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hepatitis C
Interventions: Telaprevir, Peginterferon alfa-2a, Ribavirin, Vitamin D; Drug · Dietary Supplement
Lead sponsor: Timothy Morgan, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 4
States / cities: Long Beach, California • Minneapolis, Minnesota • Kansas City, Missouri + 1 more

Conditions: Chronic Hepatitis C
Interventions: valopicitabine, Pegylated Interferon Alfa; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 175 participants
Timeline: Started 2005
U.S. locations: 19
States / cities: Phoenix, Arizona • San Diego, California • San Mateo, California + 16 more

Conditions: Chronic Hepatitis C, Chronic Hepatitis B
Interventions: Regression of fibrosis, Specific risk factors related to hepatocellular carcinoma; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Little Rock, Arkansas • Chapel Hill, North Carolina

Conditions: Hepatitis C Infection
Interventions: Placebo, SCY-635, Pegasys, Copegus; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: San Francisco, California • Durham, North Carolina • San Antonio, Texas

Conditions: Chronic HCV
Interventions: Quality of Life Therapy, Supportive Therapy; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 21 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C Virus
Interventions: Velpatasvir; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Saint Paul, Minnesota + 1 more

Conditions: Chronic Hepatitis C
Interventions: PSI-7977, Daclatasvir, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 17
States / cities: Coronado, California • San Diego, California • Aurora, Colorado + 13 more

Conditions: Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated interferon alfa 2a; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more

Conditions: Chronic Hepatitis C
Interventions: SOF, RBV, Peg-IFN; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 67
States / cities: Birmingham, Alabama • Bakersfield, California • Colton, California + 53 more

Conditions: Human Immunodeficiency Virus (HIV), Hepatitis C, Chronic
Interventions: Not listed
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hepatitis C, HIV Infections
Interventions: Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Cincinnati, Ohio • Richmond, Virginia

Conditions: Hepatitis C
Interventions: Liver Biopsy; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B, Hepatitis C, Diabetes, COPD
Interventions: Multi-analyte Blood Test; Diagnostic Test
Lead sponsor: Helio Genomics; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Timeline: 2019 – 2028
U.S. locations: 7
States / cities: Redondo Beach, California • Coon Rapids, Minnesota • Fridley, Minnesota + 4 more

Conditions: Hepatitis C, Opiate Dependence
Interventions: Modified Directly Observed Therapy (mDOT), Self-Administered Therapy (SAT); Procedure
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hepatitis C, Liver Disease
Interventions: Alisporivir, Ribavirin; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 11
States / cities: Bakersfield, California • Lancaster, California • San Diego, California + 6 more

Conditions: Hepatitis C
Interventions: Infergen and ribavirin; Drug
Lead sponsor: Kadmon Corporation, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 4
States / cities: Atlanta, Georgia • New Orleans, Louisiana • Harrisburg, North Carolina + 1 more

Search by objective public record fields.

Genetics of Hepatitis C Virus Infection

California MEPS Hub

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study

Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Study in Healthy Volunteers to Evaluate a Human Monoclonal Antibody Against Hepatitis C

The SIM-SOF Trial for Hepatitis C

Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1

A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C

The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study

Study of SCY-635, Pegasys and Copegus in Hepatitis C

Quality of Life Therapy for Adults With Hepatitis C Virus and Cirrhosis Awaiting Liver Transplantation

Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment

Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System

Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV

Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer

Effective Treatment of Hepatitis C in Substance Users

Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option

Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin